Franziska Sabrina Karras

Dr. Franziska Sabrina Karras

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Pathology - Research and Practice
Verified
Journal Article
Closed access
ARAlbert Roessner
Albert Roessner
SFSabine Franke
Sabine Franke
JSJulian Schreier
Julian Schreier
SUSarah Rebecca Ullmann
Sarah Rebecca Ullmann
FKFranziska Sabrina Karras
Franziska Sabrina Karras
DJDoerthe Jechorek
Doerthe Jechorek

28 February 2024 in Pathology - Research and Practice
Verified
Journal Article
Open access
FKFranziska Sabrina Karras
Franziska Sabrina Karras
MKManfred Kunz
Manfred Kunz
Melanoma is a very aggressive, rapidly metastasizing tumor that has been studied intensively in the past regarding the underlying genetic and molecular mechanisms. More recently developed treatment modalities have improved response rates and overall survival of patients. However, the majority of patients suffer from secondary treatment resistance, which requires in depth analyses of the underlying mechanisms. Here, melanoma models based on patients-derived material may play an important role. Consequently, a plethora of different experimental techniques have been developed in the past years. Among these are 3D and 4D culture techniques, organotypic skin reconstructs, melanoma-on-chip models and patient-derived xenografts, Every technique has its own strengths but also weaknesses regarding throughput, reproducibility, and reflection of the human situation. Here, we provide a comprehensive overview of currently used techniques and discuss their use in different experimental settings.

2 September 2023 in Pathology - Research and Practice
Verified
Journal Article
Closed access
FKFranziska Sabrina Karras
Franziska Sabrina Karras
MBM. Bonsack
M. Bonsack
SSS. Seifert
S. Seifert
LFL. Friedrich
L. Friedrich
MKM. Kunz
M. Kunz

11 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SUSarah Rebecca Ullmann
Sarah Rebecca Ullmann
JSJulian Schreier
Julian Schreier
JCJuan Carlos Alberto Uribe Caputi
Juan Carlos Alberto Uribe Caputi
MGMarilena Georgiades
Marilena Georgiades
JUJoana Maria Ullmann
Joana Maria Ullmann
ARAlbert Roessner
Albert Roessner
Background/Objectives: Recurrences and metastases occur frequently in chordoma and are the main factors influencing overall survival. However, prognostic biomarkers for recurrence remain limited. This study examines whether quantitative nuclear morphometry can capture recurrence evolution and whether it aligns with immunophenotype and genomic profiling. Methods: A total of 26 specimens from 12 adults (8 patients with non-recurrent tumors and 4 patients with multiple long-term recurrences and metastases over 7 to 16 years) were analyzed using whole-exome sequencing, immunohistochemistry, and nuclear morphometry. Results: Imaging studies and routine histology showed no consistent differences between groups. Morphometry revealed substantial intertumoral variability among non-recurrent tumors and significant longitudinal nuclear remodeling throughout recurrences, dominated by increased nuclear size and asymmetry, as well as altered shape. Primary tumors from patients who later recurred had smaller, more asymmetric, and denser nuclei than non-recurrent tumors. Recurrent samples showed higher proliferation and decreased lamin A/C expression, with focal disruption and detachment from the nuclear envelope in pleomorphic nuclei. The tumor mutational burden was low overall, varied between patients and timepoints, and tended to be higher in recurrent cases. Conclusions: Quantitative nuclear morphometry, integrated with immunophenotyping and genomic profiling, captures recurrence-associated phenotypic remodeling in chordoma and may provide a quantitative framework for future digital pathology or AI approaches, pending validation in larger cohorts.

28 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ARAlbert Roessner
Albert Roessner
SFSabine Franke
Sabine Franke
JSJulian Schreier
Julian Schreier
SUSarah Rebecca Ullmann
Sarah Rebecca Ullmann
FKFranziska Sabrina Karras
Franziska Sabrina Karras
A histological evaluation remains the cornerstone of diagnosing highly malignant osteosarcoma, having demonstrated its efficacy and reliability over several decades. However, despite these advancements, misdiagnoses with severe consequences, including inadequate surgical procedures, continue to occur. Consequently, there is a pressing need to further enhance diagnostic security. Adjunct immunohistochemical approaches have demonstrated significant effectiveness in regard to cancer diagnostics, generally. However, their utility for identifying highly malignant osteosarcoma is limited. Molecular genetic findings have significantly improved the diagnosis of Ewing’s sarcoma by identifying specific translocations and have been used to detect specific IDH gene mutations in chondrosarcoma. Nevertheless, molecular genetic alterations in highly malignant osteosarcoma exhibit a high degree of complexity, thereby limiting their diagnostic utility. Given that only 1–2% of the human genome comprises protein-coding sequences, the growing number of non-coding regulatory RNAs, which are increasingly being elucidated, has garnered substantial attention in the field of clinical cancer diagnostics. Over the past several years, patterns of altered non-coding RNA expression have been identified that facilitate the distinction between benign and malignant tumors in various organs. In the field of bone tumors, the experience of this approach has been limited thus far. The divergent expression of microRNAs has demonstrated utility for differentiating osteosarcoma from osteoblastoma and discriminating between osteosarcoma and giant-cell tumors of bone and fibrous dysplasia. However, the application of non-coding RNA expression patterns for the differential diagnosis of osteosarcoma is still in its preliminary stages. This review provides an overview of the current status of non-coding RNAs in osteosarcoma diagnostics, in conjunction with a histological evaluation. The potential of this approach is discussed comprehensively.

7 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ARAlbert Roessner
Albert Roessner
SFSabine Franke
Sabine Franke
JSJulian Schreier
Julian Schreier
SUSarah Rebecca Ullmann
Sarah Rebecca Ullmann
FKFranziska Sabrina Karras
Franziska Sabrina Karras
The histological evaluation remains the cornerstone of diagnosing highly malignant osteosarcoma, having demonstrated its efficacy and reliability over several decades. However, even in recent times misdiagnoses with severe consequences, including inadequate surgical procedures, have persisted. Consequently, there is a considerable need to enhance diagnostic security further. Adjunct immunohistochemical approaches have proven highly effective in cancer diagnostics generally but have been limited in their utility for differentiating highly malignant osteosarcoma. Molecular genetic findings have significantly improved the diagnosis of Ewing’s sarcoma by identifying specific translocations and chondrosarcoma by detecting specific IDH-gene mutations. However, molecular genetic alterations in highly malignant osteosarcoma exhibit a very high degree of complexity, limiting their diagnostic utility. Given that only 1-2% of the human genome consists of protein-coding sequences, the increasing number of non-coding regulatory RNAs, which are increasingly being described, has garnered significant attention in the field of clinical cancer diagnostics. Over the past several years, patterns of altered non-coding RNA expression have been identified that facilitate the distinction between benign and malignant tumors in various organs. In the field of bone tumors, the experience with this approach has been limited so far. Divergent expression of microRNAs has demonstrated utility for differentiating osteosarcoma from osteoblastoma and discriminating osteosarcoma from giant cell tumor of bone and fibrous dysplasia. However, the application of non-coding(nc)RNA expression patterns for the differential diagnosis of osteosarcoma is still in its nascent stages. This review provides an overview of the current status of ncRNAs in osteosarcoma diagnostics, in conjunction with histological evaluation. The potential of this approach is discussed in detail.